Metabolic syndrome and microalbuminuria predict renal outcome in non-diabetic patients with primary hypertension: The MAGIC study

Journal of Human Hypertension

Volumn 26, Issue 3, 2012, Pages 149-156

  Leoncini, G ^a   Viazzi, F ^a   Vercelli, M ^a,b   Deferrari, G ^a   Pontremoli, R ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

chronic kidney disease; metabolic syndrome; microalbuminuria; primary hypertension

Indexed keywords

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; ALBUMINURIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INCIDENCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK;

EID: 84857052579     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2011.2     Document Type: Article

References (30)

1. Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl 2005; 98: S7-S10.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1): S1-S266.
3. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769-1778. (Pubitemid 40923091)
4. Ritz E. Metabolic syndrome and kidney disease. Blood Purif2008; 26: 59-62.
5. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004; 27: 2444-2449. (Pubitemid 39281399)
6. Weir MR. Microalbuminuria and cardiovascular dis-ease. Clin JAm Soc Nephrol 2007; 2: 581-590.
7. Verhave JC, Gansevoort RT, Hillege HL, Bakker SJ, De Zeeuw D, de Jong PE. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl 2004; 92: S18-S21.
8. van der Velde M, Halbesma N, de Charro FT, Bakker SJ, de Zeeuw D, de Jong PE et al. Screening for albuminuria identifies individuals at increased renal risk. JAm Soc Nephrol 2009; 20: 852-862.
9. Mann JF, Gerstein HC, Yi QL, Lonn EM, Hoogwerf BJ, Rashkow A et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003; 14: 641-647. (Pubitemid 36246007)
10. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complica-tions. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553. (Pubitemid 28319935)
11. Zavaroni I, Bonini L, Gasparini P, Zuccarelli A, Dall'Aglio E, Barilli L et al. Dissociation between urinary albumin excretion and variables associated with insulin resistance in a healthy population. JIntern Med 1996; 240: 151-156. (Pubitemid 26308671)
12. Mykkänen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998; 7: 793-800. (Pubitemid 28201810)
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
14. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet 2005; 366: 1059-1062. (Pubitemid 41338752)
15. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and manage-ment of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [published corrections appear in Circulation 2005; 112:e297 and Circulation 2005; 112:e298]. Circulation 2005; 112: 2735-2752. (Pubitemid 41532612)
16. Pontremoli R, Sofia A, Ravera M, Nicolella C, Viazzi F, Tirotta A et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MA-GIC Study. Microalbuminuria: A Genoa Investigation on Complications. Hypertension 1997; 30: 1135-1143. (Pubitemid 27476170)
17. Andersson T, Alfredsson L, Källberg H, Zdravkovic S, Ahlbom A. Calculating measures of biological interac-tion. Eur JEpidemiol 2005; 20: 575-579.
18. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. JAm Soc Nephrol 2005; 16: 2134-2140. (Pubitemid 41716445)
19. Kitiyakara C, Yamwong S, Cheepudomwit S, Dom-rongkitchaiporn S, Unkurapinun N, Pakpeankitvatana V et al. The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort. Kidney Int 2007; 71: 693-700. (Pubitemid 46494568)
20. Ninomiya T, Kiyohara Y, Kubo M, Yonemoto K, Tanizaki Y, Doi Y et al. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis 2006; 48: 383-391. (Pubitemid 44247252)
21. Luk AO, So WY, Ma RC, Kong AP, Ozaki R, Ng VS et al. Metabolic syndrome predicts new onset of chronic kidney disease in 5829 patients with type 2 diabetes: a 5-year prospective analysis of the Hong Kong Diabetes Registry. Diabetes Care 2008; 31: 2357-2361.
22. Palaniappan L, Carnethon M, Fortmann SP. Associa-tion between microalbuminuria and the metabolic syndrome: III NHANES. Am J Hypertens 2003; 16: 952-958. (Pubitemid 37315495)
23. Leoncini G, Ratto E, Viazzi F, Vaccaro V, Parodi D, Parodi A et al. Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hyperten-sive patients. J Intern Med 2005; 257: 454-460. (Pubitemid 40613071)
24. Knol MJ, van der Tweel I, Grobbee DE, Numans ME, Geerlings MI. Estimating interaction on an additive scale between continuous determinants in a logistic regression model. Int JEpidemiol 2007; 36: 1111-1118. (Pubitemid 350018555)
25. Rothman KJ, Greenland S, Walker AM. Concepts of interaction. Am JEpidemiol 1980; 112: 467-470. (Pubitemid 10029548)
26. Paniagua OA, Bryant MB, Panza JA. Role of endo-thelial nitric oxide in shear stress-induced vasodila-tion of human microvasculature: diminished activity in hypertensive and hypercholesterolemic patients. Circulation 2001; 103: 1752-1758. (Pubitemid 32291412)
27. Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997; 34: 55-68. (Pubitemid 27261913)
28. Ryan MC, Fenster Farin HM, Abbasi F, Reaven GM. Comparison of waist circumference versus body mass index in diagnosing metabolic syndrome and identify-ing apparently healthy subjects at increased risk of cardiovascular disease. Am JCardiol 2008; 102: 40-46.
29. Panoulas VF, Ahmad N, Fazal AA, Kassamali RH, Nightingale P, Kitas GD et al. The inter-operator variability in measuring waist circumference and its potential impact on the diagnosis of the metabolic syndrome. Postgrad Med J2008; 84: 344-347.
30. Kern EF, Maney M, Miller DR, Tseng CL, Tiwari A, Rajan M et al. Failure of ICD-9-CM codes to identify patients with comorbid chronic kidney disease in diabetes. Health Serv Res 2006; 4: 564-580. (Pubitemid 43374287)